Blog

Societies

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Photo taken from Grainne O’Kane/X

Jun 5, 2024, 13:27

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Grainne O’Kane, Medical Oncologist and Clinical Research Fellow at Trinity St. James’s Cancer Institute, shared a post on X:

“GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.

Important to remember most on PDAC trials less than 70 years.
Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
Need to identify who can benefit and discuss with patients.”

GIANT trial

Source: Grainne O’Kane/X

5‐Fluorouracil ASCO ASCO24 cancer Gemcitabine plus nab-Paclitaxel (GnP) Grainne O’Kane OncoDaily Oncology Overall survival (OS) pancreatic ductal adenocarcinoma (PDAC)

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage